Prostate Cancer News on BioPortfolio

Darolutamide submitted for European marketing authorization

Orion CorporationÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂ Press ReleaseCommunicationsÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂ 8 March 2019 at 830 a.m. EET Darolutamide submitted for European marketing authorization Orion Corporation and Bayer today ann...

FDA Grants Breakthrough Designation to Paige.AI

Expedites Product Development and Provides Priority Regulatory Review For Paige.AIs Pioneering ClinicalGrade Artificial Intelligence in Pathology Paige.AI the leading startup in computational pathology focused on bu...

Blue Earth Diagnostics Celebrates Five Year Anniversary

Blue Earth Diagnostics a leading molecular imaging diagnostics company recently celebrated the companys five year anniversary. During this time Blue Earth Diagnostics has delivered five years of innovation and continued growth...

LowDose Aspirin Doesn't Prolong Survival in Prostate Cancer

TUESDAY March 5 2019 Will an aspirin a day keep prostate cancer at bayNot necessarily according to new research.Danish scientists say lowdose aspirin doesn't seem to reduce a man's risk of death from prostate cancer but it may slow down...

Stereotactic Body RT Promising for Low IntermediateRisk PCa

TUESDAY March 5 2019 In men with lowrisk and intermediaterisk prostate cancer stereotactic body radiotherapy is associated with low rates of severe toxic events and high rates of biochemical control according to a study published online...

Bayer files prostate cancer drug darolutamide in Japan

Bayer has filed its prostate cancer drug darolutamide with Japanese regulators in an attempt to ratchet up the pressure on rivals Johnson & Johnson and PfizerAstellas.With darolutamide developed in partnership with Finlands Orion Corporat...

Darolutamide submitted for marketing authorization in Japan

Orion CorporationÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂÂ Press release 5 March 2019 at 8.00 a.m. EET Darolutamide submitted for marketing authorization in Japan Regulatory submission based on positive data from the Phase III ARAMIS trial Orion Corporation a...

MDxHealth SelectMDx Liquid Biopsy Test for Prostate Cancer Included in the 2019 Italian Society of Urology Guidelines

NEWS RELEASE   Â MDxHealth's SelectMDx Liquid Biopsy Test for Prostate Cancer Included in the 2019 Italian...

Pages